Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 56.8%

Gross margin was 56.8% in Q1 FY2026, up 5.4 pp from a year earlier. On a trailing-twelve-month basis it was 65.0%, down 0.3 pp year over year. Over 3 fiscal years it widened by 3.7 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
56.8%-26.6 pp QoQ
Last fiscal yearDec 2025
67.9%-11.4 pp YoY
LTMMar 2026
65.0%-0.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+5.4 pp——
1 year-11.4 pp——
3 years+3.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
67.9%
Year-over-year change
-11.4pp

Gross Margin vs competitors

How ESPR compares with its peers on the latest reported figures

  • ESPR's LTM Mar 2026 gross margin of 65.0% is the 3rd highest of the 8 companies compared; the peer median is 44.4%.
  • Its year-over-year change of -0.3 pp is the 4th highest of 8, against a peer median of -4.9 pp.
  • Over three fiscal years its change of +3.7 pp compares with a peer median of +4.9 pp.
ESPR Competitors Peer median
Gross Margin for ESPR and competitors
Company Period LTM level YoY 3-year change
OFIXOrthofix Medical Inc.LTM Mar 202669.0% +1.9 pp-6.1 pp
SIGASIGA Technologies, Inc.LTM Mar 202665.4% -11.2 pp-22.0 pp
ESPREsperion Therapeutics, Inc.LTM Mar 202665.0% -0.3 pp+3.7 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 202663.5% -4.9 pp+2.1 pp
EBSEmergent BioSolutions Inc.LTM Mar 202644.4% +8.0 pp+4.9 pp
SNDLSNDL Inc.LTM Mar 202627.2% +0.6 pp+7.6 pp
RGNXREGENXBIO Inc.LTM Mar 2026-0.1% -76.7 pp+36.5 pp
ABSIAbsci CorporationLTM Mar 2026-1316.9% -337.8 pp+605.7 pp
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding ESPR) 44.4%-4.9 pp+4.9 pp

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.45M75.48M116.33M332.31M403.14M
Cost of Revenue14.22M26.97M43.27M68.6M129.22M
Gross Profit64.23M48.51M73.07M263.71M273.91M
Gross Margin81.9%64.3%62.8%79.4%67.9%
Research & Development105.98M118.93M86.11M46.24M47.85M
Selling, General & Admin184.99M109.08M142.52M163.07M165.79M
Operating Expenses290.96M228.01M228.63M209.31M213.64M
Depreciation & Amortization612K500K164K63K105K
EBITDA(222.14M)(176.35M)(150.11M)7.57M63.87M
EBITDA Margin-283.2%-233.7%-129.0%2.3%15.8%
Operating Income(226.73M)(179.5M)(155.56M)54.4M60.27M
Operating Margin-289.0%-237.8%-133.7%16.4%15.0%
Interest Income00003.5M
Interest Expense46.35M56.81M58.98M59.25M84.6M
Other Income / Expenses(42.38M)(54.16M)(53.69M)(106.15M)(81.11M)
Income Before Tax(269.11M)(233.66M)(209.25M)(51.75M)(20.84M)
Pre-Tax Margin-343.0%-309.6%-179.9%-15.6%-5.2%
Income Tax Expense00001.84M
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Net Margin-343.0%-309.6%-179.9%-15.6%-5.6%
EPS (Basic)(11.03)(4.33)(2.03)(0.28)(0.11)
EPS (Diluted)(11.03)(4.33)(2.03)(0.28)(0.11)
Weighted Avg Shares28.9M66.41M103.11M187.18M207.87M
Weighted Avg Shares (Diluted)28.9M66.41M103.11M187.18M207.87M

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.